Background and purpose Current evidence suggests that the time lag from the publication of randomised clinical trial results to changes in prescribing behaviour for drugs is gradually reducing. However, the effect of results of clinical trials of devices and nonpharmacological interventions on clinical practice is less clear.
INTRODUCTION
Randomised clinical trials (RCT) are the 'gold standard' for defining the efficacy and effectiveness of interventions and have been instrumental in shaping clinical practice over the last 60 years. Translation of such research into clinical practice can be very slow, as seen for some earlier RCTs, 1 although the time lag between trial result for drug interventions and change in practice may be reducing. [2] [3] [4] However, the effect of trial results for other types of interventions on clinical practice is less clear.
Graduated compression stockings (GCS) reduce deep vein thrombosis (DVT) and, potentially, pulmonary embolism (PE) in hospitalised immobile patients undergoing surgery. 5 However, whether GCS are effective in patients with acute stroke was unclear 6 until the definitive 'Clots in Legs Or sTockings after Stroke' (CLOTS-1) trial showed that thigh-length GCS had no benefit. 7 Subsequently, the CLOTS-2 trial found that DVT rates were higher with below-knee than thigh-length GCS. 8 Since the ongoing international multicentre 'Efficacy of Nitric Oxide in Stroke' (ENOS) trial 9 collects information prospectively on GCS use and length and venous thromboembolism (VTE) outcomes (following our previous work in this area 6 ), we hypothesised that GCS use would have altered following the publication of CLOTS-1 trial. Here we compare the use of GCS in acute stroke before and after the CLOTS-1 trial publication using data from ENOS.
METHODS

CLOTS trials
The CLOTS family of three multicentre randomised controlled trials is assessing the benefit of external compression on preventing DVT in patients with acute ischaemic stroke or primary intracerebral haemorrhage (PICH). CLOTS-1, published in The Lancet on 27 May 2009, compared thigh-length GCS with avoidance of GCS and concluded that there was no difference in the rate of symptomatic or asymptomatic popliteal or femoral DVT between the two treatment groups. 7 CLOTS-2 compared thigh-length GCS versus below-knee GCS and was published on 20 September 2010 in the Annals of Internal Medicine
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; DVT rates were higher in participants randomised to below-knee GCS. The ongoing CLOTS-3 trial is testing intermittent pneumatic compression versus avoidance of intermittent pneumatic compression (http://www.dcn.ed.ac.uk/clots/, accessed 20 May 2012). All three trials recorded both symptomatic and asymptomatic DVT.
ENOS trial
ENOS is an ongoing international multicentre prospective randomised controlled single-blind trial with blinded outcome assessment investigating the management of blood pressure in acute stroke. 9 Participants with an acute ischaemic 
Data collection
Information on baseline demographic and clinical variables is entered into the ENOS database by the local investigator using a secure web interface. Information on GCS use during the first week after randomisation and type (thigh-length, below-knee) are collected prospectively at discharge from hospital or on death; some patients in ENOS were also part of CLOTS-1, although co-enrolment was not recorded. The occurrence of symptomatic DVT and/or PE is collected in two ways: (1) prospectively using specific questions at day 7 after randomisation (end of blood pressure treatment); and (2) through serious adverse event (SAE) reporting at any time between baseline and the final follow-up at day 90. As a result, early VTE events may be recorded by both approaches thereby allowing crossreferencing. Information on DVT and PE events recorded as SAEs are assessed by an adjudicator (authors DB, NS) blinded to treatment assignment and use of GCS.
Statistical methods
Since ENOS is ongoing, all analyses were performed blinded to treatment assignment (GTN vs no GTN, continue vs stop prestroke antihypertensive therapy). Data are given as number (%) or mean (SD). Comparisons between GCS usage groups were assessed using the χ 2 test (categorical) or Fisher exact test (categorical data where any cell in the cross-tabulation table had a value <5) and analysis of variance (ANOVA) (continuous data); multiple comparisons were tested with the Scheffe test. Logistic regression was used to assess the relationship between VTE events and GCS use with adjustment for age, sex and baseline stroke severity (Scandinavian Stroke Scale (SSS)); anticoagulant use was not entered into this model in the absence of information on its use at baseline. GCS and VTE rates were analysed by geographical region: Asia (China, Hong Kong, India, Singapore, Sri Lanka), Australasia (Australia, New Zealand), Europe (Italy, Poland, Romania, Spain), North America (Canada) and UK. Statistical analysis was performed using SPSS (Apple Mac V.18); significance was set at p<0.05.
RESULTS Participants
Between July 2001 and April 2011, 2291 participants were enrolled into ENOS. Participants enrolled before February 2003 were excluded from the present analysis as recruitment was limited to a few centres. Data on GCS usage were available for 1971 participants with ischaemic stroke or PICH. The characteristics of the included participants are shown in table 1 and are representative of the trial as a whole (mean age 70 years, 57.8% male). The participants came from the UK (62.0%), elsewhere in Europe (11.8%), Asia (21.7%), Australasia (2.7%) and North America (1.7%).
Of the 1971 participants, 498 (25.3%) wore GCS (table 1) . Participants prescribed thigh-length or below-knee GCS had more severe stroke and were more likely to have a total anterior circulation syndrome (TACS) 10 than those without GCS (table 1) . Other baseline characteristics were largely similar between those prescribed and not prescribed GCS.
GCS use
Prior to the publication of CLOTS-1, 7 GCS use was common (>50%) in the UK, Australasia and North America (Canada) but infrequent in Asia (China, Hong Kong, India, Singapore, Sri Lanka) (5.4%) and Europe (Italy, Poland, Romania, Spain) (2.9%) (table 2). Following the publication of CLOTS-1, GCS use declined rapidly in the UK (from 60.7% to 3.6%, p<0.001) but not in Australasia (56.8% before publication vs 70.0% after publication, p=0.24, although this observation is based on small numbers) or in any other region (table 2) . The shift in practice was seen within 3 months of the trial publication and was sustained thereafter (figures 1 and 2). Regions with low GCS use before CLOTS-1 remained low afterwards.
Prior to CLOTS-1 publication there was no discernible trend for change between use of thigh-length and below-knee GCS (data not shown), not least because sites tended to use only one or other type of GCS or none at all (table 3) . The dramatic reduction in GCS use after CLOTS-1 precludes any assessment of the effect of CLOTS-2 ( published in 2010 8 ) on the use of thigh-length versus below-knee GCS.
Co-recruitment between ENOS and CLOTS
In the UK, 31 sites were taking part in both ENOS and CLOTS-1/2 (both protocols permitted this) during the time period examined here. Importantly, there was no difference in the use of GCS between sites that were co-recruiting patients and those that were only recruiting into ENOS both before (61.2% vs 59.2%, p=0.38) and after (3.8% vs 3.4%, p=0.48) the publication of CLOTS-1. It was not possible to determine the total number of patients co-enrolled into ENOS and CLOTS-1/ 2 since the trials do not have systems for linking information on individual patients (for confidentiality reasons). However, in our site in Nottingham, of 56 patients recruited into CLOTS-2 and 179 into ENOS, only six patients were co-enrolled into both trials.
Antithrombotics
Anticoagulation, a non-randomised intervention in ENOS, was being used at day 7 in 262 (13.3%) participants as per the local investigator's practice: thigh-length GCS, 34 (16.6%); belowknee GCS, 37 (12.6%); no GCS, 191 (13.0%). Aspirin, another non-randomised intervention, was used in 1453 patients (73.7%): thigh-length GCS, 153 (74.6%); below-knee GCS, 220 (75.1%); no GCS, 1080 (73.3%). In the UK there was no change in the use of anticoagulation before and after the publication of CLOTS-1 (12.0% vs 12.2%, p=0.51).
Venous thromboembolism
The rate of symptomatic VTE (DVT and/or PE) was low overall at 1.8% (table 4) and associated with increasing stroke severity ( p<0.001). VTE was very low in participants with no GCS (1.4%) or thigh-length GCS (1.0%), but higher in those with below-knee GCS (4.4%; p=0.005). Compared with no GCS, below-knee GCS was associated with increased VTE (OR 2.47, 95% CI 1.20 to 5.71, p=0.014); in contrast, thigh-length GCS was not associated with VTE (OR 0.49, 95% CI 0.11 to 2.13, p=0.34). In multiple variable modelling with adjustment for age, sex and baseline stroke severity (SSS), VTE was significantly associated with GCS use ( p=0.017).
DISCUSSION
The primary aim of this ENOS trial subgroup analysis was to assess the effect of the results of the CLOTS-1 trial on GCS use in acute stroke. CLOTS-1 showed that thigh-length GCS do not prevent DVT in patients with recent stroke. 7 Before the results of CLOTS-1 the overall use of GCS was high in ENOS at 39.4%, although this varied regionally with high usage (>50%) in Australasia, North America and the UK but low use in Asia and the rest of Europe (<6%). Following CLOTS-1, GCS use fell rapidly to 4.8% within 3 months. The change was seen clearly in the UK where GCS use fell from 60.7% to 3.5%. The most plausible interpretation is that the neutral CLOTS-1 trial dramatically changed stroke practice with GCS no longer being used routinely. This change will have saved healthcare time and finances since widespread GCS use is expensive in both cost (GCS cost approximately £20 per patient) and time of administration (15 min per patient per day).
The rate of investigator-reported VTE was low in ENOS at 1.9%. When assessed by GCS use, participants without GCS or those with thigh-length GCS had a rate of symptomatic DVT of 0.7% compared with 2.0% in those with below-knee GCS. This result mirrors the results of CLOTS-1 and CLOTS-2 where DVT rates were comparable between thigh-length GCS and no GCS, 7 but higher in below-knee GCS than thigh-length GCS.
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Data are number (%), median (IQR) or mean (SD). Comparison of three groups (no GCS, below GCS and thigh length GCS) by ANOVA (continuous data) and χ 2 test or Fisher exact test (frequency data)
. Significance is p value for the null hypothesis that there is no difference between the three groups. BP, blood pressure; ENOS, Efficacy of Nitric Oxide Stroke; IHD, ischaemic heart disease; LACS, Lacunar syndrome; PACS, partial anterior circulation syndrome; PICH, primary intracerebral haemorrhage; POCS, posterior circulation syndrome; TACS, total anterior circulation syndrome. When adjusted for baseline covariates, below-knee stockings were significantly associated with increased VTE compared with no GCS or thigh-length GCS. Whether this reflects that below-knee GCS cause DVT compared with thigh-length GCS (as suggested by CLOTS-1/2), indication bias ( physicians are more likely to prescribe below-knee GCS than no GCS in patients they perceive to be at risk) or site bias (hospitals tended to use one or other type of GCS) is unclear. Several studies have reported a change in prescribing behaviour following the publication of randomised controlled trials of drug interventions. First, annual US α-blocker prescriptions declined by 26% (from 5.15 million to 3.79 million) over 3 years after the The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) results were published in 2000. There are fewer data for devices, but the publication of the International Subarachnoid Aneurysm randomised Trial increased the proportion of patients who had aneurysmal coiling. 11 Both the rate and scale of change in GCS use seen in ENOS after the CLOTS-1 publication are much higher than the above studies.
Aberegg and colleagues report that physicians are more likely to abandon a harmful therapy than adopt a beneficial therapy and argue that this is most likely to be due to a bias in the physician's evaluation of medical evidence. 12 The present study is consistent with this observation-that is, where a regularly used intervention with no benefit was abandoned rapidly. Although CLOTS-1 did not show a difference in VTE rates between GCS and no GCS, a concern was the presence of increased skin breaks, ulcers, blisters and skin necrosis in patients with GCS, 7 so the trial may have been viewed as clinically 'negative' rather than 'neutral'.
The present study has several limitations. First, the data come from a randomised trial with selection of participants on the basis of inclusion and exclusion criteria. Specifically, patients were excluded if they did not have motor weakness, did not have an elevated blood pressure or were dependent (mRS>2) prior to stroke onset. Second, the hospitals taking part in ENOS may be considered to be research active and therefore not representative of clinical practice at non-trial sites. However, this is less likely to be a consideration in the UK where 84 of approximately 200 acute stroke sites 13 are participating in ENOS, these including a mix of teaching/tertiary care and non-teaching/secondary care hospitals. Third, the use of some interventions that may reduce VTE and influence the use of GCS (eg, rehydration, early mobilisation and prophylactic heparin) were not recorded. Nevertheless, these are widely used and this issue is unlikely to have introduced a systematic bias. Fourth, VTE rates in ENOS will be an underestimate since events are not actively sought, although this is unlikely to be a problem as it is a consistent issue across all sites. Fifth, GCS rates may have been influenced by the use of prophylactic heparin, although its routine use can be questioned since reductions in VTE come at the price of increased bleeding. 14 15 Importantly, there was no increase in the use of heparin after the publication of CLOTS-1. Sixth, much of the data came from the UK, so temporal changes in other countries are based on limited data. In this respect, there were few data for some regions of the world, particularly North America and Australasia. Seventh, some patients were co-recruited into ENOS and CLOTS-1/2 thereby moderating GCS use according to randomisation. While it was not possible to determine how many patients were in both ENOS and CLOTS, co-enrolment was probably a minor occurrence as suggested by data from the Nottingham centre. Importantly, there was no difference in the use of GCS between sites that co-recruited into ENOS and CLOTS-1/2 and those that did not. Finally, centres that participate actively in a trial are more likely to introduce the experimental treatment into routine practice, 16 but co-recruitment into CLOTS did not influence the adoption of trial results in this study. In spite of these caveats, the data come from a highfidelity trial with prospective collection of data on GCS use and blinded adjudication of DVT and PE events.
In summary, this study indicates that neutral results from a large trial can change practice dramatically. In the present case, the failure of GCS to reduce DVT in patients with recent stroke, as shown in CLOTS-1, was associated with a large reduction in GCS use. Importantly, DVT and PE rates were low and do not appear to have been adversely affected by stopping routine GCS use. As a result, the dramatic reduction in the use of GCS is very likely to have been highly cost-effective. 
